New York, NYNCT06946225Now EnrollingIRB Ready

Cutaneous Melanoma Clinical Trial in New York, NY

Access cutting-edge cutaneous melanoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Immatics US, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access cutaneous melanoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cutaneous melanoma treatment provided free

Apply for This New York Location

Check if you qualify for this cutaneous melanoma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Cutaneous Melanoma Study in New York

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

Sponsor: Immatics US, Inc.

Who Can Participate

Inclusion Criteria

Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease
HLA-A\*02:01 positive
Adequate selected organ function per protocol
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Life expectancy more than 5 months
CM participants who must have disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor
SS participants must have received (or declined) at least one line of treatment (including SoC) and are still in need of further systemic therapy.
Female participants of childbearing potential must use adequate contraception prior to trial entry until 12 months after the infusion of IMA203 and 15 days after the last mRNA 4203 dose administration Other protocol defined inclusion criteria could apply

Exclusion Criteria

History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
Pregnant or breastfeeding
Serious autoimmune disease
History of cardiac conditions as per protocol
Prior allogenic stem cell transplantation or solid organ transplantation
Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
History of hypersensitivity to cyclophosphamide, fludarabine, or IL-2
History of hypersensitivity to mRNA-based medicines
Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection
Any condition contraindicating leukapheresis
Participants with lactate dehydrogenase (LDH) greater than threshold allowed per protocol
Participants with active brain metastases prior to lymphodepletion
Concurrent treatment in another clinical trial or a device trial that could interfere with the IMA203 treatment
Participants with renal impairment AND reduced bone marrow reserve per protocol Other protocol defined exclusion criteria could apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06946225) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cutaneous Melanoma Treatment Options in New York, NY

If you're searching for cutaneous melanoma treatment options in New York, NY, this clinical trial (NCT06946225) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cutaneous melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cutaneous melanoma clinical trials near you to find additional studies recruiting in your area.

More Melanoma Trials in New York, NY

See all melanoma clinical trials recruiting in New York — not just this study.

Browse Melanoma Trials in New York →

Browse More Trials by Condition

Melanoma TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY